3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Breast Neoplasms
3
Prostatic Neoplasms
2
Melanoma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Thrombocytosis
1
Sarcoma
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Liver Metastases From Colorectal Cancer (mCRC)
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tucatinib
1
niraparib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
abemaciclib
1
Trastuzumab
1
Tissue Banks
1
Ringer's acetate
1
Immunoglobulins, Intravenous
1
Fulvestrant
1
Diet
1
Blood Specimen Collection
1
Biological Therapy
1
Albumins
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
abemaciclib
×
Gastrointestinal
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled